Operating Margin
-147%
Trailing 12 months · Through 30 Jun 2023
Molekule Group, Inc. financial metrics
Period Q2 2023 · Filed 14 Aug 2023
Key metrics snapshot
Current Ratio
2.27x
Period-end balance · Through 30 Jun 2023
YoY relative change: -87%
Quick Ratio
0.43x
Period-end balance · Through 30 Jun 2023
YoY relative change: -97%
Debt-to-equity
1.12x
Period-end balance · Through 30 Jun 2023
Revenues YoY
18574%
Quarter · Through 30 Jun 2023
Profitability
| Metric | Latest value | YoY relative change |
|---|---|---|
| Operating Margin |
-147%
Trailing 12 months · 30 Jun 2023
|
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
2.27x
Period-end balance · 30 Jun 2023
|
-87% |
| Quick Ratio |
0.43x
Period-end balance · 30 Jun 2023
|
-97% |
| Debt-to-equity |
1.12x
Period-end balance · 30 Jun 2023
|
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| Revenues YoY |
18574%
Quarter · 30 Jun 2023
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
34,654,459
Period-end balance · 09 Aug 2023
|
+125% |
| Common Stock, Shares, Outstanding |
34,046,500
Period-end balance · 30 Jun 2023
|
+121% |
| Common Stock, Value, Issued |
$340,465
Period-end balance · 30 Jun 2023
|
+121% |
| Weighted Average Number of Shares Outstanding, Basic |
33,017,565
Reported period · 30 Jun 2023
|
+138% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$6,568,044
Period-end balance · 30 Jun 2023
|
+855% |
| Accounts Receivable, after Allowance for Credit Loss, Current |
$2,210,700
Period-end balance · 30 Jun 2023
|
+7780% |
| Accrued Liabilities, Current |
$5,868,740
Period-end balance · 30 Jun 2023
|
+439% |
| Additional Paid in Capital |
$83,184,034
Period-end balance · 30 Jun 2023
|
+225% |
| Assets |
$125,440,012
Period-end balance · 30 Jun 2023
|
+281% |
| Assets, Current |
$39,344,231
Period-end balance · 30 Jun 2023
|
+28% |
| Cash and Cash Equivalents, at Carrying Value |
$5,269,376
Period-end balance · 30 Jun 2023
|
-82% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$5,899,118
Period-end balance · 30 Jun 2023
|
-80% |
| Common Stock, Par or Stated Value Per Share |
0.01
Period-end balance · 30 Jun 2023
|
0% |
| Common Stock, Shares Authorized |
110,000,000
Period-end balance · 30 Jun 2023
|
0% |
| Common Stock, Shares, Issued |
34,046,500
Period-end balance · 30 Jun 2023
|
+121% |
| Deferred Income Tax Liabilities, Net |
$1,504,526
Period-end balance · 30 Jun 2023
|
+435% |
| Earnings Per Share, Basic |
-1
Trailing 12 months · 30 Jun 2023
|
-21% |
| Earnings Per Share, Diluted |
-1
Trailing 12 months · 30 Jun 2023
|
+7.5% |
| Goodwill |
$21,031,064
Period-end balance · 30 Jun 2023
|
|
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest |
-$33,695,916
Trailing 12 months · 30 Jun 2023
|
-191% |
| Interest Expense |
$1,443,009
Reported period · 30 Jun 2023
|
|
| Inventory, Net |
$29,432,880
Period-end balance · 30 Jun 2023
|
+2830% |
| Liabilities |
$84,734,956
Period-end balance · 30 Jun 2023
|
+407% |
| Liabilities and Equity |
$125,440,012
Period-end balance · 30 Jun 2023
|
+281% |
| Liabilities, Current |
$17,296,455
Period-end balance · 30 Jun 2023
|
+874% |
| Operating Income (Loss) |
-$31,908,474
Trailing 12 months · 30 Jun 2023
|
-152% |
| Operating Lease, Liability, Current |
$2,746,961
Period-end balance · 30 Jun 2023
|
|
| Operating Lease, Liability, Noncurrent |
$8,245,493
Period-end balance · 30 Jun 2023
|
|
| Operating Lease, Right-of-Use Asset |
$10,952,143
Period-end balance · 30 Jun 2023
|
|
| Other Assets, Noncurrent |
$184,854
Period-end balance · 30 Jun 2023
|
+753% |
| Property, Plant and Equipment, Gross |
$9,499,734
Period-end balance · 30 Jun 2023
|
+303% |
| Property, Plant and Equipment, Net |
$8,626,031
Period-end balance · 30 Jun 2023
|
+291% |
| Research and Development Expense |
$2,262,633
Trailing 12 months · 30 Jun 2023
|
-14% |
| Share-based Payment Arrangement, Expense |
$4,601,371
Trailing 12 months · 30 Jun 2023
|
+79% |
| Stockholders' Equity Attributable to Parent |
$40,705,056
Period-end balance · 30 Jun 2023
|
+151% |
Comparisons, sources and research notes
Sources and sharing
Molekule Group, Inc. Financial Facts
- Context
- Latest metrics period: Q2 2023
- Latest reported value
- Operating Margin -147%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q2 2023
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q2 2023.
- Most recent SEC facts end date on this page: 09 Aug 2023.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for Molekule Group, Inc.
Latest financial period: Q2 2023. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
14 Aug 2023
Page type
Company facts
Latest period
Q2 2023
SEC-backed company facts were refreshed from filings filed on 14 Aug 2023.
Benchmark Context
How Operating Margin compares
Operating Margin does not yet have enough prior-period data for a historical comparison on this page.
Compared with
Compared with Molekule Group, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Operating Margin already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q2 2023.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Revenue on this page
Revenue is the sales a company reports from customers before most expenses are subtracted.
Why people care
People start here to understand business scale and whether demand is growing before they ask about margins or cash flow.
How to read it
Check the latest reported period first, then compare the same quarter or year against prior periods so seasonality does not distort the story.
Compare next
Compare revenue with gross profit, operating income, and operating cash flow to see whether sales are turning into healthy economics.
Revenue can jump because of acquisitions, pricing changes, or revenue-recognition rules, and reporting periods may differ across companies.
Open a live SEC-backed example
Filing notes and source
Key facts
- Molekule Group, Inc. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q2 2023.
- Headline metric: Operating Margin -147%.
Change
- Comparable YoY change is unavailable for this metric.
- Most recent SEC facts end date: 09 Aug 2023.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2023-08-09) highlights Operating Margin -146.8%, Current Ratio 2.27x, and Quick Ratio 0.43x.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
No market comparison
Low confidence
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
Fair value per share
n/a
Market price
n/a
PEG ratio
n/a
Enterprise value
-$507.6M
Equity value
n/a
DCF fair value scenarios
Bear
n/a
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Base
n/a
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Bull
n/a
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
n/a
Market price market EV / SEC revenue
Market enterprise value is unavailable
EV/EBITDA
n/a
Market price market EV / SEC EBITDA
Market enterprise value is unavailable
P/E
n/a
Market price market price / SEC EPS
Market cap is unavailable
P/S
n/a
Market price market cap / SEC revenue
Market cap is unavailable
P/B
n/a
Market price market cap / SEC equity
Market cap is unavailable
PEG
n/a
P/E / DCF Growth Assumption
P/e or positive growth is unavailable
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- -$34.85M
- Trailing SEC FCF
- Reported FCF
- -$34.85M
- Net income
- -$13.52M
- EBITDA
- -$31.19M
- Cash
- $5.27M
- Debt
- n/a
- Equity
- $40.71M
- Shares
- 28,889,604
Input periods, units and SEC sources
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
- Operating cash flow: -33,655,977.0 USD · through 2023-06-30 · prior annual + current YTD − prior YTD SEC source SEC source SEC source
- Capital expenditures: 1,198,670.0 USD · through 2023-06-30 · prior annual + current YTD − prior YTD SEC source SEC source SEC source
- Cash and equivalents: 5,269,376.0 USD · through 2023-06-30 SEC source
- Debt: unavailable on a verified comparable basis
Data confidence notes
- Debt unavailable: no complete usd debt balance at the latest balance date
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Dcf base free cash flow: trailing free cash flow is not positive
- Dcf confidence is low for this sec-only free cash flow estimate
- Ticker missing for issuer
- Debt missing: equity value and market ev unavailable
- Base free cash flow is negative; dcf output is mechanically computed but high risk
- Peg unavailable: market price is missing
Compare This Company Through SEC-backed Metrics
Use these links to compare Molekule Group, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.
Revenues YoY
Latest value: 18574%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
66.9/100
Balanced Confidence low
Financial Health
- Current Ratio
- 2.27x
- Quick Ratio
- 0.43x
- Debt to Equity
- 1.12x
Strengths
Current Ratio and Revenues YoY
Watchpoints
Operating Margin
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first